Moderna shares surged after a melanoma vaccine developed with Merck succeeded in a large clinical trial. This was reported by Qazaqyia.kz citing Reuters.
The vaccine, based on Moderna's mRNA technology, demonstrated efficacy in treating melanoma, an aggressive form of skin cancer. The successful trial marks a significant step in developing new cancer treatments.
Moderna and Merck are jointly developing the vaccine, and the results confirmed its safety and effectiveness. The news positively impacted the company's stock price, increasing investor confidence.
Further details about the vaccine's market release and availability have not been disclosed yet, but this achievement opens new possibilities in the fight against cancer.